艾力斯股价小幅上扬伏美替尼片拟纳入优先审评

金融界2025-07-10

艾力斯股价最新报92.87元，较前一交易日上涨0.60%。盘中最高触及94.28元，最低下探91.50元，成交金额达2.91亿元。该公司属于化学制药板块，专注于创新药研发。其自主研发的甲磺酸伏美替尼片是一种表皮生长因子受体酪氨酸激酶抑制剂，为1类新药。2025年一季度公司实现营业收入10.98亿元，净利润4.10亿元。7月9日公司公告显示，甲磺酸伏美替尼片用于治疗EGFR20外显子插入突变...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550654253?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-10 00:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550654253","market":"sh","top_or_hot":-1,"title":"艾力斯股价小幅上扬 伏美替尼片拟纳入优先审评","media":"金融界","content":"<div>\n<p>艾力斯股价最新报92.87元，较前一交易日上涨0.60%。盘中最高触及94.28元，最低下探91.50元，成交金额达2.91亿元。该公司属于化学制药板块，专注于创新药研发。其自主研发的甲磺酸伏美替尼片是一种表皮生长因子受体酪氨酸激酶抑制剂，为1类新药。2025年一季度公司实现营业收入10.98亿元，净利润4.10亿元。7月9日公司公告显示，甲磺酸伏美替尼片用于治疗EGFR20外显子插入突变...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/07/10001251595504.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>艾力斯股价小幅上扬 伏美替尼片拟纳入优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n艾力斯股价小幅上扬 伏美替尼片拟纳入优先审评\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-10 00:12 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.jrj.com.cn/2025/07/10001251595504.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>艾力斯股价最新报92.87元，较前一交易日上涨0.60%。盘中最高触及94.28元，最低下探91.50元，成交金额达2.91亿元。该公司属于化学制药板块，专注于创新药研发。其自主研发的甲磺酸伏美替尼片是一种表皮生长因子受体酪氨酸激酶抑制剂，为1类新药。2025年一季度公司实现营业收入10.98亿元，净利润4.10亿元。7月9日公司公告显示，甲磺酸伏美替尼片用于治疗EGFR20外显子插入突变...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/07/10001251595504.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://finance.jrj.com.cn/2025/07/10001251595504.shtml","article_id":"2550654253","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550654253","pubTimestamp":1752077524,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"艾力斯股价最新报92.87元，较前一交易日上涨0.60%。其自主研发的甲磺酸伏美替尼片是一种表皮生长因子受体酪氨酸激酶抑制剂，为1类新药。2025年一季度公司实现营业收入10.98亿元，净利润4.10亿元。7月9日公司公告显示，甲磺酸伏美替尼片用于治疗EGFR20外显子插入突变NSCLC的适应症申请被纳入拟优先审评品种公示名单，公示期至7月15日。该药品新增适应症尚需经过审评、检查等环节，最终审批结果存在不确定性。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688578":"艾力斯","BK0239":"医药制造"},"translate_title":"Ellis stock price rose slightly, fumetinib tablets are planned to be included in priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688578":1},"content_text":"艾力斯股价最新报92.87元，较前一交易日上涨0.60%。盘中最高触及94.28元，最低下探91.50元，成交金额达2.91亿元。该公司属于化学制药板块，专注于创新药研发。其自主研发的甲磺酸伏美替尼片是一种表皮生长因子受体酪氨酸激酶抑制剂，为1类新药。2025年一季度公司实现营业收入10.98亿元，净利润4.10亿元。7月9日公司公告显示，甲磺酸伏美替尼片用于治疗EGFR20外显子插入突变NSCLC的适应症申请被纳入拟优先审评品种公示名单，公示期至7月15日。该药品新增适应症尚需经过审评、检查等环节，最终审批结果存在不确定性。当日主力资金净流出1641.03万元，占流通市值的0.04%。风险提示：药品审批存在不确定性，市场竞争可能加剧，研发进展不及预期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550654253","isCrawlerRequest":true}

艾力斯股价小幅上扬 伏美替尼片拟纳入优先审评

精彩评论

艾力斯股价小幅上扬伏美替尼片拟纳入优先审评